{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:45:12Z","timestamp":1782711912532,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,28]]},"DOI":"10.7759\/cureus.111692","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:07:17Z","timestamp":1782709637000},"source":"Crossref","is-referenced-by-count":0,"title":["Life-Threatening Secondary Adrenal Crisis Triggered by Pembrolizumab-Induced Hypophysitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Aye Nyein","family":"Thu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Babar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10260-8","article-title":"Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly","volume":"44","author":"Adashek JJ","year":"2025","unstructured":"Adashek JJ, Moran JA, Le DT, Kurzrock R. Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly. Cancer Metastasis Rev. 2025, 44:43. 10.1007\/s10555-025-10260-8","journal-title":"Cancer Metastasis Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event","volume":"13","author":"Doodnauth AV","year":"2021","unstructured":"Doodnauth AV, Klar M, Mulatu YS, Malik ZR, Patel KH, McFarlane SI. Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event. Cureus. 2021, 13:e15465. 10.7759\/cureus.15465","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.83400","article-title":"Adult hypopituitarism: are we missing or is it clinical lethargy?","volume":"15","author":"Brar KS","year":"2011","unstructured":"Brar KS, Garg MK, Suryanarayana KM. Adult hypopituitarism: are we missing or is it clinical lethargy?. Indian J Endocrinol Metab. 2011, 15:170-4. 10.4103\/2230-8210.83400","journal-title":"Indian J Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi MN","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MT, Wu Y, Carroll PV. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016, 85:331-9. 10.1111\/cen.13063","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari SM","year":"2019","unstructured":"Ferrari SM, Fallahi P, Elia G, et al.. Autoimmune endocrine dysfunctions associated with cancer immunotherapies. Int J Mol Sci. 2019, 20:2560. 10.3390\/ijms20102560","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04659-5","article-title":"Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features","volume":"149","author":"Esteves-Ferreira S","year":"2023","unstructured":"Esteves-Ferreira S, Rosinha P. Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features. J Cancer Res Clin Oncol. 2023, 149:7925-32. 10.1007\/s00432-023-04659-5","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507830-life-threatening-secondary-adrenal-crisis-triggered-by-pembrolizumab-induced-hypophysitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:07:17Z","timestamp":1782709637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507830-life-threatening-secondary-adrenal-crisis-triggered-by-pembrolizumab-induced-hypophysitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.111692","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}